Pro-Pharmaceuticals to start dosing in three new Davanat trials

By Elaine Rigoli

Tampa, Fla., Aug. 30 - Pro-Pharmaceuticals, Inc. said it continues to make "excellent" progress in clinical trials with Davanat, its lead product candidate.

"The outstanding results from our phase 1 and phase 2 trials of end-stage patients, who were refractory to chemotherapy, have led us to initiate three clinical trials with line-one and line-two patients," chief executive officer David Platt said in a company news release.

"We believe we will improve the clinical benefit to patients over the current standard of care for colorectal and biliary cancer. We plan to begin dosing patients shortly."

Davanat is a complex carbohydrate drug that, when given in combination with chemotherapeutic agents, demonstrates reduced toxicity and increased efficacy by targeting the delivery and penetration of the chemotherapy to the tumor, the company said.

Pro-Pharmaceuticals is based in Newton, Mass., and develops novel nanotechnology carbohydrate therapeutic compounds.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.